Objective To study vaginal as opposed to cervical human papillomavirus (HPV) acquisition with regard to true prevalence, HPV types, and the role of co-factors in virgins and after their sexual debut.
Introduction
Mayer-Rokitansky-K€ uster-Hauser syndrome (MRKHS) is a malformation of the female genital tract characterised by the agenesis of vagina and uterus in the presence of normal † Contributed equally as senior author. ovarian function and normal external genitalia. The main therapeutic goal is giving affected women the opportunity of having sexual intercourse by the creation of a neovagina. One of the most common methods is the laparoscopic Vecchietti technique, which does not use any autotransplanted tissue. Our modification of the original procedure creates a neovagina of adequate size and secretory capacity for normal coitus. 1, 2 The procedure is fast, effective and minimally traumatic, has a very low long-term complication rate and provides very satisfactory long-term functional results. 2 However, most of the literature has focused on surgical outcomes after neovaginoplasty and little is known about neovagina-associated diseases. Although, Frega et al. 3 previously reported on human papillomavirus (HPV) -related diseases after different techniques of neovaginoplasty, emphasising the need for HPV evaluation after surgery. Neovaginal pH and microbiological cultures provided results consistent with those of normal vaginal flora. 3 Different from most other surgical techniques the laparoscopically assisted neovaginoplasty creates a neovagina covered by a physiological glycogen-secreting epithelium, histologically comparable to a normal vagina. 3, 4 We were wondering if the fact that a neovagina is 'surgically created' comes with a higher risk for the acquirement of an HPV infection and HPV-related cancer and as a consequence if these women have to be even more encouraged to be vaccinated against HPV or to avoid known risk factors like smoking.
On the other hand, compared with other intraepithelial neoplasias such as cervical or vulvar intraepithelial neoplasia, there is still little understanding about the impact of vaginal HPV infections, the natural course of vaginal intraepithelial neoplasia (VAIN) and its capacity for progression or regression, 5 and there is controversial data about the HPV detection rate in VAIN lesions. [6] [7] [8] With this study we were in the unique position to be able to evaluate women regarding acquisition, follow up and impact of vaginal HPV infections, as these women are normally seen before having sexual intercourse (due to not having a functional vagina) and during follow up after neovaginoplasty.
Using this highly compliant patient cohort suffering from a rare disease our aim was to study for the first time vaginal (as opposed to cervical) HPV acquisition with regard to true prevalence, HPV types, and the role of cofactors before and after sexual debut.
Methods

Study design and participants
This is a prospective study combining vaginal smears with clinical data including the history of young women presenting to the Department of Women's Health, T€ ubingen University Hospital, T€ ubingen, Germany between November 2011 and July 2017.
The study was approved in advance by the Ethics Committee of the University of T€ ubingen (205/2014BO1). Informed consent was obtained from each woman before recruitment.
Tests for HPV were taken at surgery. Routine clinical follow-up examinations were carried out 1, 3, 6 and ≥ 11 months after surgery for long-term follow up. Each follow-up visit included: general gynaecological and standardised vaginal examinations, recording of any neovaginoplasty-related signs or symptoms, vaginal cytology [Papanicolaou (Pap) smear] and HPV tests.
In this study patients or public were not actively involved in the research work.
Cytology
Conventional vaginal Pap smears were taken routinely and examined at the cytological laboratory of the Department of Women's Health using the Second Munich Cytological Classification (MN II).
HPV detection
Eligible consenting women had single liquid-based vaginal samples taken, using a Rovers Cervex-Brush, at each examination. Samples were placed in ThinPrep transport medium (Hologic, San Diego, CA, USA) according to the manufacturer's guidelines (liquid-based cytology). HPV detection was performed without knowledge of the cytological diagnosis. HPV testing was performed with the DNAbased hybrid capture 2 (HC2) test according to the standard protocol recommended by the manufacturer (Qiagen, Hilden, Germany) with the high-risk (HR) and low-risk (LR) probes. The HC2 HR probe detects high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, whereas the LR probe detects HPV types 6, 11, 42, 43 and 44. The threshold for a positive HC2 result was 1 relative light unit (RLU). PreservCyt specimens were retested when RLU/cut-off ratios between 1.0 and 2.5 were obtained. If the initial retest result was positive (RLU/cut-off ratio of 1.0), then the specimen was reported as positive. If the retest was negative (RLU/cut-off ratio of < 1.0), then a second repeat test (third result) was performed to generate a final result. In addition, to detect actively infected cells the Aptima HPV RNA-based assay (Hologic) was performed following the manufacturer's instructions. The initial recommended cut-off value of a signal/cut-off ratio of 1.0 at the time of study initiation was used in this study. In all cases we performed in addition SPF10 [ that has an extremely high sensitivity and is able to detect even infections below the cut-off level of the HC2 and the Aptima assay. Strips were scanned and analysed automatically with a flatbed scanner and the LIRAS software (Fujirebio Europe, Ghent, Belgium). In cases with positive HC2 test (due to described cross-reactivity), 10 but negative LiPA results, we performed a nested PCR with the PGMY09/11 primer pairs first and used the amplicon for the second PCR using the GP5 + /6 + primer sets (abbreviated as 'nested PCR'). Amplicons were then sequenced using the GP6 + primer and the respective HPV type was identified by comparing the sequence with the NCBI data base using BLAST.
Statistical analysis
All statistical analyses were done using R version 3.3.2 (The R foundation for Statistical Computation, Vienna, Austria). We show number and percentages or means with standard deviation (SD), median and ranges as appropriate. Differences in numbers for nominal data were tested by Fisher's exact test, differences in values for ordinal or continuous data were assessed by Wilcoxon Rank test. Agreement of different HPV tests (Aptima, HC2 using the HR and LR probe and the LiPA Extra genotyping test) was assessed by Cohen's j. Time to first intercourse after surgery was estimated by Kaplan-Meier method. The significance level in all tests was chosen as 5%.
Some characteristics are not available for all women, therefore percentages refer to different sample sizes.
Results
Participants
About 186 women with MRKHS (with 663 HPV tests taken) could be included, who had at least one test done at surgery. All women had confirmed MRKHS, 121 (65.1%) had type 1 and 65 (34.9%) had type 2 and all of them underwent laparoscopically assisted creation of a neovagina.
The mean age of women at surgery was 20.1 years (SD 5.4 years, median 18.1 years, minimum 14.5 years, maximum 43.4 years).
Mean body mass index (BMI) of the women (n = 181, five unknown) was 22.1 kg/m 2 (SD 4.6, minimum 15.6, maximum 44.1).
Apart from one woman with Crohn's disease and four with Hashimoto's thyroiditis, there were no known autoimmune or infectious diseases (hepatitis, HIV, etc.). Apart from the woman with Crohn's disease, no other participant was on immunosuppressive drugs at surgery or thereafter. Three of the women admitted regular use of cannabis, one of whom also had a history of cocaine and ecstasy use until 6 months before surgery.
Postoperative cytology and HPV tests were performed between mean 4.5 months (SD 5.6, median 3.0, minimum À5.1, maximum 34.5) and mean 9.1 months (SD 7.0, median 9.2, minimum À0.1, maximum 34.5) after surgery. Negative numbers show tests that were done before surgery.
HPV prevalence and HPV types
Overall, in 83 vaginal samples from 41 different women at least one of the HPV tests was positive (for details regarding the different tests see Table 1 ). The level of agreement between Aptima, HR and LR was high as shown in Table 2 .
The prevalence of 41/186 = 22.0% was the same as in a young German female population (22%) reported by Iftner et al. 11 As reported previously, the percentage of HPVpositive individuals was highest in the age group > 20 years of age (Figure 1) . 11 Subclinical infections detected by LiPA only were already apparent in the age group below the age of 17 years ( Figure 1) .
Twenty women were HPV-negative at surgery and acquired an infection. Two of them became HPV-negative within 1½ years and two became HPV-negative and again positive within 1½ years.
Twenty-one women were HPV-positive already at surgery. Three of them became HPV-negative within 1 year and one became HPV-negative and again positive within a 2-year period. The individual courses of the women (n = 41) who were positive in at least one HPV test are given in Figure 2 .
Thirty-three different HPV types were detected with the LiPA test (Figure 3) . The type distribution detected in HPV-positive women was not very different from the normal female population in Germany, 11 with HPV 16 being the commonest type, followed by 56, 66, 31, 51 and 53, but it varied for HPV types 87, 89 and 90 detected by the PCR/sequencing approach ( Figure 3 ). There was no significant difference between HPV-positive and HPV-negative women (Wilcoxon test, P = 0.821) regarding the number (3.7 and 3.5 tests per woman, respectively) and time-points of HPV tests performed (mean 139 days after surgery, median 77 days after surgery, SD 169 days after surgery versus mean 138 days after surgery, median 90 days after surgery, SD 171 days after surgery, respectively).
Relationship between HPV results, sexual activity and other risk factors
There were no known immunosuppressive diseases or drugs reported.
Overall 15.8% (25/158) of women were current or past smokers, 29.5% (43/146) had sexual contacts before surgery and 36.0% (45/125) were vaccinated against HPV.
In total, 28.6% (10/35) of the HPV-positive women were current or past smokers. The proportion of smokers among women with at least one positive HPV test was significantly higher compared with those who always had negative test results [12.2% (15/123); P = 0.033; OR = 2.86, 95% CI 1.11-7.49).
In all, 54.3% (19/35) of the HPV-positive women were sexually active before surgery. Patients with always negative HPV tests had their first sexual contact significantly later compared with those with at least one positive test (LogRank test, P < 0.001) (for details see Table 3 ).
Thirty percent (9/30) of the HPV-positive women were vaccinated against HPV, but it is not known to us if the vaccination took place before any sexual contacts. There is no significantly different proportion of vaccinated women among those with a positive HPV test (30.0%, 9/30) compared with those who were always negative (37.9, 36/95) (P = 0.516); however, this is based on a small number of cases. Importantly, no infections with HPV types 6, 11, 16 or 18 could be detected in vaccinated women. Instead, the following types were identified in vaccinated women: genotypes 31, 33, 42, 51, 53, 59, 87 and 89.
The percentage of HPV-positive women was not different in MRKHS type 1 and 2 (78 and 22%, respectively) compared with those who were always negative (61 and 39%, respectively) (P = 0.063).
HPV positivity at surgery and risk factors
The percentage of HPV positivity was significantly higher in women with sexual contacts before surgery compared with those without (P = 0.002, OR 5.24, 95% CI 1.89-16.12). Though, seven of the HPV-positive women declared no sexual contacts before surgery. HPV positivity at surgery did not depend significantly on the number of partners before surgery (P = 0.071), nor on smoking (P = 0.286).
HPV positivity 1 year (11-13 months) after surgery and risk factors
Women who had sexual intercourse within the first year after surgery were significantly more often HPV-positive (8/28) compared with women who did not (0/16) (P = 0.037). This effect was not statistically significant when restricting the results to women who were HPVnegative at surgery (6/25 with sexual intercourse compared with 0/16 without; P = 0.065).
Smoking did not have a significant effect on HPV positivity after 1 year over all women (P = 0.068), but had a significant effect on the acquirement of an infection in women who were HPV-negative at surgery (P = 0.033).
There was no significant difference in grade of epithelialisation in women with negative (mean grade of 
Relationship with cytology results
Three hundred and sixty-seven Pap results could be correlated with an HPV test result. In total we found Pap I in 210, Pap II in 150, Pap IIw in one and Pap IIID in six tests. As expected, Pap IIID cytological findings were mostly positive in all HPV tests except for the low-risk test (Table 4) .
Discussion
Main findings
This comprehensive study uses for the first time young virgin women suffering from a rare disease to investigate acquisition, types and courses of vaginal HPV infections over time and puts them in relation to known risk factors.
By using very sensitive tests (detecting subclinical infections also) we could show that overall more than one-fifth (22.0%) of the women were HPV-positive in at least one of the tests used. This prevalence of vaginal HPV infections is the same as for HPV infections of the cervix in an epidemiological observational study on young women in Germany 11 and the prevalence was highest in the age group > 20 years of age. In addition, the type distribution detected in HPV-positive women was comparable to that in the normal female population in Germany, with HPV 16 being the most frequently detected type, 11 followed by HPV 56, 66, 31, 51 and 53. Recently, HPV 16 was the main virus type to be associated with the development of VAIN. 5, 7 In contrast, HPV 87, 89 and 90 were identified more often than in the cervical swabs from the general population. 11 The very sensitive LiPA test detected these types, which cannot be classified as HR or LR so far and therefore the potential and clinical relevance is unknown.
Types 18 and 45, which are more frequently detected associated with glandular lesions, were as rare as in the normal population, as expected.
As in the general population, the overall rate of acquisition was clearly associated with sexual activity and smoking habits.
One could speculate that a lower grade of epithelialisation at sexual debut could cause more HPV infections. But, we found no significant difference in grade of epithelialisation in women with negative or positive HPV tests 1 year after surgery. Surprisingly, out of 367 Pap smears, only six were abnormal with Pap IIID (MN II) and no obvious vaginal lesion was detected.
Strengths and limitations
Strengths of the study include the prospective epidemiological nature and the size of the patient cohort with this rare disease. The main advantage of the study is the inclusion of primarily virgin women who become sexually active thereafter. An additional strength is the use of very sensitive tests, which are able to also detect subclinical infections in order to identify the true prevalence of HPV infections in women with MRKHS.
A limitation is that, although individual courses of the HPV infection are given in Figure 3 , we do not have enough data on the clearance of HPV infections in women with MRKHS who are positive for HPV. Our follow-up data do not allow any statements on whether clearance is higher than in the normal population, as data on HPV clearance specifically in vaginal epithelium are also scarce.
Interpretation
An HPV prevalence and type distribution comparable with those in the general population seems to indicate that the vaginal epithelium created by the surgical procedure is normal with respect to susceptibility of the abundant HPV types and in this respect very similar to cervical epithelium, but not higher.
Thirty percent (9/30) of the HPV-positive women were vaccinated against HPV, but no infections with HPV types 6, 11, 16 or 18 could be detected in vaccinated women, demonstrating good vaccine efficacy and probably preferred usage of the quadrivalent vaccine. Interestingly, HPV types 31 and 33 were among the commonest in HPV-positive women who had been vaccinated against HPV, a fact that emphasises once more the importance of including these types within the recent nonavalent vaccine. From our experience, the vaccination is often not recommended to women with MRKHS because of the missing cervix. There are no described serious adverse events from the vaccine and our data provide the first hints for protection of the vagina in this patient group. Hence, and because of the prevalence shown, the vaccination of women with MRKHS should be strongly recommended.
At surgery, the percentage of HPV-positivity was significantly higher in women with sexual contacts before surgery compared with those without. Nevertheless, seven of the HPV-positive women declared no sexual contacts before surgery, which might be explained by using other sexual practices (e.g. petting), which we did not specifically asked about. A few studies have examined HPV infection among children and female virgins showing transmission from mother to child, by nonpenetrative sex and by nonsexual skin-to-skin contact 12 and it has been shown that genital HPV was common among male virgins. 13, 14 HPV positivity at surgery did not depend on the number of partners before surgery, nor on smoking. One could speculate that the derivatives of tobacco cannot be stored in women with vaginal aplasia who have almost non-existant vaginal epithelium (before surgery) and therefore infection constitutes no risk.
Also, smoking did not have a significant effect on HPV positivity after 1 year over all women, but had a significant effect on the acquirement of an infection in those who were HPV-negative at surgery.
One reason for the small number of Pap smear abnormalities could be the relatively short follow-up period after surgery (maximum 34.5 months after surgery). On the other hand, at least in the general population with a normal uterus and cervix, VAIN is a rare disease, representing < 1% of all intraepithelial neoplasia of the female genital tract. Although, it can affect women of any age, it is more common in women > 50 years of age, 5, 15 whereas the mean age of our patients was only 20.1 years at surgery.
The development of squamous carcinomas in skin graft neovaginas and adenocarcinomas in intestinal neovaginas has been reported. 16 To our knowledge, no carcinoma of the neovagina has been reported after (modified) Vecchietti technique or self dilatation so far. But as women acquire HPV infections with a prevalence equal to the normal population, one would expect them to be at risk for premalignant and malignant diseases of the neovagina. Like all other women, individuals who underwent the creation of a neovagina should receive a vaccination against HPV and be included in the routine gynaecological care including HPV tests at the beginning of sexual activity and thereafter.
Conclusion
In conclusion, the rate of vaginal HPV acquisition and the distribution of HPV types in previously virgin individuals after creation of a neovagina are comparable to those of cervical infections in the general population and are clearly associated with sexual activity and with smoking habits. Abnormal Pap smears are, however, rarely seen, which might be due to the relatively short follow-up period in this study.
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